ENDO PHARMACEUTICALS HOLDINGS INC 4
4 · ENDO PHARMACEUTICALS HOLDINGS INC · Filed Mar 14, 2005
Insider Transaction Report
Form 4
Loverro Frank J
10% Owner
Transactions
- Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−1,875$4,538→ 2,509,989 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (1,875 underlying) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−1,579$3,821→ 53,060,781 total(indirect: By LLC) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−5,205$12,596→ 680,672 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (5,205 underlying) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−4,860$11,761→ 53,054,426 total(indirect: By LLC) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−5,205$12,596→ 53,049,221 total(indirect: By LLC) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−1,800$4,356→ 53,062,359 total(indirect: By LLC) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$3.42/sh−1,495$5,113→ 53,059,286 total(indirect: By LLC) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−1,875$4,538→ 53,047,345 total(indirect: By LLC) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−4,860$11,761→ 4,616,007 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (4,860 underlying) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−800$1,936→ 1,982,756 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (800 underlying) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−14,215$34,400→ 685,877 total(indirect: By LLC)Exercise: $2.42From: 2004-11-29Exp: 2007-08-26→ Common Stock (14,215 underlying) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−14,215$34,400→ 53,064,159 total(indirect: By LLC) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$2.42/sh−800$1,936→ 53,045,872 total(indirect: By LLC) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$3.00/sh−673$2,019→ 1,459,754 total(indirect: By LLC)Exercise: $3.00From: 2004-12-15Exp: 2007-08-26→ Common Stock (673 underlying) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−1,579$3,821→ 1,298,782 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (1,579 underlying) - Exercise of In-Money
Common Stock, par value $.01 per share
2005-03-10$3.00/sh−673$2,019→ 53,046,672 total(indirect: By LLC) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$3.42/sh−1,495$5,113→ 1,003,239 total(indirect: By LLC)Exercise: $3.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (1,495 underlying) - Exercise of In-Money
Call Option (obligation to sell)
2005-03-10$2.42/sh−1,800$4,356→ 1,151,885 total(indirect: By LLC)Exercise: $2.42From: 2004-12-15Exp: 2007-08-26→ Common Stock (1,800 underlying)
Footnotes (3)
- [F1]Kelso Investment Associates V, L.P. ("KIA V") is the designated filer.
- [F2]KIA V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KIA V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.
- [F3]Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KIA V, by virtue of his status as a general partner of the general partner of KIA V, and each individual shares investment and voting power along with the other general partners of KIA V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.